SciELO - Scientific Electronic Library Online

 
vol.27 issue10Duloxetine and others tricyclic antidepressants: pharmacodynamic effects on lower urinary tractAntimicrobial susceptibillity of escherichia coli associated with community-acquired urinary tract infections author indexsubject indexarticles search
Home Pagealphabetic serial listing  

Services on Demand

Journal

Article

Indicators

Related links

Share


Actas Urológicas Españolas

Print version ISSN 0210-4806

Abstract

RODRIGUEZ CORDON, M.; FERRER ALBIACH, E.  and  FERRER ALBIACH, C.. Current multiapproach treatment of metastatic prostate cancer. Actas Urol Esp [online]. 2003, vol.27, n.10, pp.767-782. ISSN 0210-4806.

Prostate cancer is one of the commonest causes of cancer-related death in the western world. The morbi-mortality associated is usually a direct consequence of metastatic spread to bone, in up to 50% of patients at first presentation. The aim of treatment of metastatic patients is to alleviate and to prevent the distressing symptoms. The approach include hormone-therapy, radiotherapy, radionuclides, surgery, chemotherapy, bisphosphonates and new drugs (agents that inhibit angiogenesis, inmmunotherapy and therapies that affect the differentiation). Decisions about therapy must also take into consideration the androgen-dependent or independent, so hormone-therapy is the first step of the treatment; the number and location of bone metastases; the severity of symptoms; the available of therapies; the status performance of patient; the prognosis and the cost-effect relationship. Some treatments have established indications whereas others are still in process of study in order to determinate their efficacy, their model of treatment and their indications. This article revises and updates these treatments.

Keywords : Prostate; Metastatic; Hormone-therapy; Radiotherapy; Chemotherapy; Bisphosphonates; Radionuclides; Surgery; New approaches.

        · abstract in Spanish     · text in Spanish     · Spanish ( pdf )

 

Creative Commons License All the contents of this journal, except where otherwise noted, is licensed under a Creative Commons Attribution License